Abstract
Rationale of using commonantifibrotic therapy in post covid fibrosis
Abstract:
Pulmonary fibrosis can occur in the absence of any clear-cut inciting agent & cause, that happened in IPF but it is more commonly devlope following acute and/or persistent lung injury/ damage due to many causes such as : Connective tissue disorders Chronic granulomatous diseases, Medications, and different respiratory infections ( Virals & fungals) Available clinical, radiographic, and autopsy data has indicated that pulmonary fibrosis is central to severe acute respiratory distress syndrome (SARS) and MERS pathology, and current evidence suggests that pulmonary fibrosis could also complicate infection by SARS-CoV-2.
Author(s):
Dr Sm Abdullah Al Mamun
Abstract | PDF
Share this
Awards Nomination
Google scholar citation report
Citations : 275
Abstracted/Indexed in
- Google Scholar
- China National Knowledge Infrastructure (CNKI)
- Directory of Research Journal Indexing (DRJI)
- WorldCat
- Geneva Foundation for Medical Education and Research
- Secret Search Engine Labs
- CAS (Chemical Abstracting Services)
Open Access Journals
- Aquaculture & Veterinary Science
- Chemistry & Chemical Sciences
- Clinical Sciences
- Engineering
- General Science
- Genetics & Molecular Biology
- Health Care & Nursing
- Immunology & Microbiology
- Materials Science
- Mathematics & Physics
- Medical Sciences
- Neurology & Psychiatry
- Oncology & Cancer Science
- Pharmaceutical Sciences